Amylin Shareholder Sues Over $7B Sale To Bristol-Myers

Law360, New York (July 3, 2012, 6:03 PM EDT) -- A day after announcing its $7 billion sale, California diabetes drugmaker Amylin Pharmaceuticals Inc. and its board of directors were hit with a putative shareholder class action Tuesday in Delaware that alleges the sale undervalues the company.

Named plaintiff Maxine Phillips filed the shareholder suit in Delaware Chancery Court, accusing San Diego-based Amylin and its board of breaching its fiduciary duty to shareholders by approving the company's pending $7 billion sale to rival U.S. drugmaker Bristol-Myers Squibb Inc. and U.K. pharmaceutical company AstraZeneca. Phillips claims that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.